EP3437636A1 — Pharmaceutical composition comprising ezetimibe
Assigned to Adamed Sp zoo · Expires 2019-02-06 · 7y expired
What this patent protects
The invention relates to a pharmaceutical composition comprising 5 to 20 %wt. ezetimibe, 5 to 20 %wt. plastic excipient, 3 to 10 %wt. disintegrant, 1 to 12 %wt. starch, 0.5 to 1.5 %wt. silica, 0.5 to 2.5 %wt. stearic acid, wherein a weight ratio stearic acid to silica is 1:1 to 3…
USPTO Abstract
The invention relates to a pharmaceutical composition comprising 5 to 20 %wt. ezetimibe, 5 to 20 %wt. plastic excipient, 3 to 10 %wt. disintegrant, 1 to 12 %wt. starch, 0.5 to 1.5 %wt. silica, 0.5 to 2.5 %wt. stearic acid, wherein a weight ratio stearic acid to silica is 1:1 to 3: 1, and wherein the pharmaceutical composition of the invention comprises a further diluent and binder, and optionally surfactant. Furthermore, the invention relates to a tablet comprising the composition, and a use of the composition for manufacturing the tablet.
Drugs covered by this patent
- Zetia (EZETIMIBE) · Merck & Co.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.